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Abstract: Methylation of p16 and p14 genes is a common event in colorectal cancers; however, their exact role in the pre-
diction of patients’ outcome is unclear. We conducted this retrospective study to evaluate their potential predictive and/or 
prognostic roles. Methylation-specific PCR was used to examine the methylation status of p16 and p14 in pretherapeutic and 
preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. The methylation status of the examined 
genes did not affect the response to preoperative chemoradiotherapy (CRT), recurrence rate and overall survival. However, 
patients with a simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) 
expression showed a significantly worse response to CRT (p=0.005 and p=0.038, respectively). Moreover, patients with both 
p16 methylation and high VEGF expression had significantly shorter overall survival (p=0.010), while no such association 
was found in patients with p14 methylation and high VEGF expression. On the other hand, a subgroup of patients with p16 
methylation and low VEGF and high epidermal growth factor receptor (EGFR) expression showed a significantly better 
response to CRT (p=0.024). The obtained results point to the importance of p16 and p14 methylation analyses in combina-
tion with VEGF and EGFR expression, aimed at better predicting treatment response and patient outcome.
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INTRODUCTION
Colon and rectal cancers are often considered to-
gether, although these two clinical entities have many 
differences in etiology and treatment strategies [1]. 
Preoperative (neoadjuvant) CRT followed by radical 
surgery has become the standard treatment for pa-
tients with locally advanced rectal cancer [2]. Despite 
reduced local recurrence rates, the responses of indi-
vidual tumors to this multimodal treatment are vari-
able and range from complete regression to complete 
resistance [3]. Better pretherapeutic patient stratifi-
cation and accurate response prediction requires the 
development of reliable molecular biomarkers.
The predictive values of potential biomarkers have 
been tested, including EGFR, the marker for cellular 
proliferation Ki-67, and one of the key mediators of 
apoptosis, B-cell lymphoma 2 (Bcl-2) protein [4,5]. 
VEGF, a primary angiogenic factor, has been fre-
quently examined since it plays a pivotal role in tu-
mor angiogenesis and strongly contributes to tumor 
malignancy [6]. However, for most marker studies, 
the results are conflicting and remain inconclusive.
The most investigated epigenetic modification 
in colorectal cancer is aberrant DNA methylation 
of 5’-Cytosine-phosphate-Guanine-3’ (CpG) islands 
within promoter regions, which is associated with 
gene silencing [7,8]. Specific methylation patterns of 
a number of tumor suppressor genes involved in color-
ectal carcinogenesis have been studied with the aim 
of defining novel epigenetic biomarkers that could be 
used in clinical practice [9,10]. The INK4a/alternate 
reading frame (ARF) locus encodes two tumor sup-
pressor proteins, P16INK4a and P14ARF, which act as key 
negative regulators of the cell cycle [11]. P16INK4a is a 
cyclin-dependent kinase inhibitor that prevents pRb 
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phosphorylation and thereby induces G1 phase arrest, 
while P14ARF indirectly facilitates p53-mediated cell-cy-
cle arrest and apoptosis by interaction with the mouse 
double minute 2 homolog (MDM2) protein [12].
In addition, there is evidence that p16 and p14 
genes may have an important role in regulation of an-
giogenesis through downregulation of VEGF expres-
sion. This regulation takes place at the transcriptional 
level through inhibition of hypoxia-inducible factor 
1-alpha (HIF-1α), which acts as a VEGF transcription 
factor [13,14]. We assumed that the methylation status 
of p16 and p14 genes could be related to the different 
levels of VEGF expression, which could have some 
clinical relevance.
Inactivation of p16 and p14 genes by promoter 
hypermethylation has been frequently reported as an 
early event in colorectal neoplasia [15,16]. However, 
correlation between the methylation status of p16 and 
p14 genes and clinical outcomes in patients with lo-
cally advanced rectal cancers is not fully established. 
Hence, in the present study, the promoter methylation 
of these two tumor suppressor genes was examined in 
order to identify the relationship between their meth-
ylation status and clinicopathological and immuno-
histochemical parameters, and to investigate whether 
the methylation status of p16 and p14 genes affects the 
response to preoperative CRT and overall survival in 
60 patients with locally advanced rectal cancer.
MATERIALS AND METHODS
Patients and tumor samples
The study was approved by the Ethical Committee 
of the Oncology Institute of Vojvodina, Sremska Ka-
menica, and all procedures were carried out with the 
prior informed consent of the patients. Our retrospec-
tive study included 60 patients (38 male, 22 female; 
median age 65 years, range 49-82 years) with locally 
advanced rectal cancer (clinical stage cT3b,cN0-2 with 
positive circumferential margin (CRM) and cT4N0-
2), who were diagnosed and treated with preoperative 
CRT at the Oncology Institute of Vojvodina, Sremska 
Kamenica, Serbia, in the period 2006-2010, according 
to the National guidelines of the Ministry of Health 
of Serbia for Diagnosis, Therapy and Management 
of colorectal cancer. Before the administration of pr-
eoperative CRT, all patients underwent tumor biopsy 
for diagnostic purpose. The neoadjuvant treatment 
consisted of total irradiation with a dose of 50.4 Gy, 
that was divided into 28 fractions of 1.8 Gy, with con-
comitant application of 5-fluorouracil (425 mg/m2) 
and leucovorin (25 mg/m2). Total mesorectal excision 
(TME) radical surgery was performed 8-10 weeks af-
ter the end of the combined treatment. The location 
of the tumor was determined by MRI in the low (≤7 
cm from the anal verge), high (>7 cm from the anal 
verge) or mid rectum (< and > than 7 cm the from 
anal verge). Pathological grading of primary tumor 
regression in posttreatment specimens was performed 
semiquantitatively by determining the amount of re-
sidual tumor cells compared with the amount of fibro-
sis. The response to neoadjuvant CRT was classified as 
positive when complete or partial remission (CR/PR) 
was detected, or as negative in the case of the presence 
of stable or progressive disease (SD/PD).
DNA extraction and methylation analysis of the 
p16 and p14 genes
The methylation status of p16 and p14 was evaluated 
on diagnostic tumor biopsies obtained as formalin-
fixed, paraffin-embedded tumor tissues. Briefly, ge-
nomic DNA was isolated from deparaffinized tumor 
specimens using standard proteinase K, phenol/
chloroform/isoamyl alcohol extraction and ethanol 
precipitation [17]. DNA methylation patterns in the 
promoter CpG islands of the p16 and p14 genes were 
determined by methylation-specific PCR (MSP). Ini-
tially, sodium bisulfite conversion of genomic DNA 
(100-500 ng) was performed using an EZ DNA Meth-
ylation-LightningTM kit (Zymo Research, Orange, CA, 
US) according to the manufacturer’s instructions. For 
MSP reactions, 1 μL out of 10 μL bisulfite modified 
DNA was used. The PCR mixture contained 1 x PCR 
buffer (16 mmol/L ammonium sulfate, 67 mmol/L 
Tris-HCL, pH 8.8, 10 mmol/L 2-mercaptoethanol), 6.7 
mmol/L MgCl2, dNTP (each at 1.25 mmol/L), primers 
(300 ng each per reaction), 5% DMSO and 0.4 mg/
mL bovine serum albumin (BSA) in a final volume 
of 25 μL. Reactions were hot-started at 95°C for 5 
min before the addition of 1 unit of Taq polymerase 
(Thermo Scientific, USA). Amplification was carried 
out in an Applied Biosystems 2720 temperature cy-
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cler for 40 cycles (45 s at 95°C, 45 s at the annealing 
temperature being specific for each primer set, and 
60 s at 72°, followed by final extension for 4 min at 
72°C). Primer sequences and annealing temperatures 
used for each reaction are listed in Table 1S [18,19]. 
Promoter regions of both genes, including the parts 
used for methylation analysis are presented in Fig. 
1S. DNA from peripheral blood lymphocytes from 
a healthy donor was used as a negative control for 
the methylated alleles. The same leukocyte DNA was 
methylated in vitro with excess SssI methyltransferase 
(New England Biolabs) to generate completely meth-
ylated DNA at all CpG sites and used as a positive 
control for all genes. PCR products were separated by 
electrophoresis on 6% acrylamide gels, stained with 
silver nitrate and sodium carbonate.
Immunohistochemical analysis of VEGF, Ki-67, 
Bcl-2 and EGFR proteins
Immunohistochemical analysis of VEGF, Ki-67, Bcl-2 
and EGFR expression was performed in the diagnostic 
biopsy specimens, and determined at the Oncology 
Institute of Vojvodina, Sremska Kamenica, as previ-
ously described [20]. According to the percentage of 
tumor cells in the given specimens with a positive 
immunohistochemical (IH) reaction, tumor samples 
were considered to have VEGF expression as follows: 
absent VEGF expression (0-1% of tumor cells with a 
positive IH reaction), weak (1.1-10% of tumor cells 
with a positive IH reaction), moderate (10.1-50% of 
tumor cells with a positive IH reaction), high VEGF 
expression (50.1-100% of tumor cells with a positive IH 
reaction); the same criteria were applied to Ki-67 and 
Bcl-2 expression. In the case of EGFR, the expression 
of EGFR protein in 0-1% of tumor cells was consid-
ered as negative, in 1.1-25% of tumor cells as weak, in 
25.1-50% as moderate, in 50.1-100% of cells as strong.
Statistical analysis
Contingency tables were analyzed using Pearson’s 
χ2-test or Fisher’s exact two-tailed test when the ex-
pected frequencies were lower than five. Continuous 
variables were compared using the Student’s t-test. 
Overall survival distributions were estimated by the 
Kaplan-Meier method and differences were evaluated 
by the Log-rank test. In all tests, a p value ≤0.05 was 
considered as statistically significant. All statistical 
analyses were performed using the Sigma Plot 10.0 
licensed statistical analysis software package.
RESULTS
p16 and p14 methylation status
Analysis of the p16 methylation status was success-
fully performed in all 60 cases, while the p14 methyla-
tion status was determined in 58/60 patients. Aber-
rant methylation of p16 and p14 genes was present in 
43.3% (26/60) and 39.6% (23/58) of the cases, respec-
tively. Concurrent methylation of p16 and p14 genes 
was detected in 11 out of 58 (18.9%) cases, while 38 
out of 60 patients (60.3%) had at least one methyl-
ated gene. Representative examples of the methylation 
analysis are shown in Fig. 1.
VEGF, Ki-67, Bcl-2 and EGFR expression status
Analysis of the expression statuses of VEGF, Ki-67, 
Bcl-2 and EGFR was successfully performed in 58/60 
cases. The absence of VEGF expression was observed 
in 37.9% (22/58) of cases, weak VEGF expression was 
detected in 13.8% (8/58) of cases, moderate expres-
sion in 34.5% (20/58) and high VEGF expression in 
Fig. 1. Analysis of p16 and p14 gene methylation status by MSP. 
The presence of a visible PCR product in lanes U indicates the 
presence of unmethylated p16 (151 bp) and p14 (132 bp) genes; 
the presence of product in lanes M indicates the presence of meth-
ylated p16 (150 bp) and p14 (122 bp) genes. Samples of rectal 
cancer 49 and 60 show p16 promoter hypermethylation, while 
samples 56 and 40 show p14 promoter hypermethylation. NL – 
normal lymphocytes as a positive control for unmethylated al-
leles, PC – in vitro methylated DNA from normal lymphocytes 
as a positive control for methylated alleles, L – molecular weight 
marker (50 bp).
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13.8% (8/58). In the case of Ki-67, weak expression 
was observed in 25.9% (15/58) of patients, moderate 
in 24.1% (14/58), while high Ki-67 expression was 
detected in 50% (29/58). Thirty-five out of 58 samples 
(60.3%) had no Bcl-2 expression, weak expression was 
detected in 8.6% (5/58) of patients, moderate in 15.5% 
(9/58), while high Bcl-2 expression was detected in 
15.5% (9/58) of cases. Finally, in the case of EGFR, 
41.4% (24/58) of the patients had no EGFR expres-
sion, weak EGFR expression was detected in 29.3% 
(17/58), moderate expression in 13.8% (8/58), and 
high EGFR expression in 15.5% (9/58) of patients. 
Representative examples of IH staining for all four 
analyzed proteins are shown in Fig. 2. In further anal-
ysis, the tumor samples were considered as having 
high VEGF, Ki-67 or Bcl-2 expression when at least 
10% of the tumor cells expressed VEGF, Ki-67 or Bcl-
2 protein, respectively. Samples were considered to 
have high EGFR expression if >25% of the tumor cells 
demonstrated membranous staining of any intensity.
Correlation of the p16 and p14 methylation 
statuses with clinicopathological and 
immunohistochemical parameters
The study of correlations between the p16 and p14 
methylation statuses and clinicopathological param-
eters is summarized in Table 1. No association was 
found between promoter methylation of either the 
p16 or p14 gene and the clinicopathological param-
eters including age, gender, tumor location (distance 
to anal verge) and clinical TNM (Tumor Node Metas-
tasis classification of malignant tumors) stage (p>0.05 
for all variables). The data representing the number of 
patients according to VEGF, Ki-67, Bcl-2 and EGFR 
expression and the gene methylation status are given 
in Table 2. There was no correlation between the p16 
and p14 methylation statuses and any IH parameter 
analyzed (p>0.05 for all variables).
p16 and p14 methylation status and response to 
neoadjuvant CRT
Of the 60 locally advanced rectal cancer cases, there 
was an equal number of patients (30/60) with positive 
(CR/PR) and negative (SD/PD) responses to neoadju-
vant CRT. In general, a better response to neoadjuvant 
CRT was observed in patients with low VEGF expres-
sion (p<0.001), low VEGF and high EGFR expression 
(p=0.014) and low Ki-67 expression (p=0.004), while 
other analyzed parameters did not affect the response 
to neoadjuvant CRT (results not shown). The meth-
ylation statuses of p16 and p14 genes were not related 
to the response to neoadjuvant CRT either (p=0.434 
and p=1.000, respectively (Table 1), so we further ex-
amined the response to the CRT according to the si-
multaneous presence of aberrant methylation of either 
p16 or p14 gene, and the different levels of expression 
of immunohistochemically determined parameters. A 
significantly worse response to CRT was observed in 
the group of patients with a simultaneous presence of 
p16 methylation and high VEGF expression (p16m/
high VEGF), as compared to the other three groups of 
patients: unmethylated p16/low VEGF, unmethylated 
p16/high VEGF, methylated p16/low VEGF (p=0.005). 
A similar association was noted for the group of pa-
tients with concurrent presence of p14 methylation 
and high VEGF expression (p14m/high VEGF), who 
showed a significantly worse response to CRT than 
Fig. 2. Representative images for immunohistochemically estimat-
ed VEGF, EGFR, Bcl-2 and Ki-67 expression. A – Negative VEGF 
reaction in tumor tissue but positive in endothelial cells (LSAB x 
100). B – Positive VEGF reaction in tumor tissue of rectal cancer 
(LSAB x 100). C – Partial barely visible EGFR membrane positivity 
in tumor tissue (LSAB x 10). D – Intense complete EGFR reaction 
in most tumor cells (LSAB x 100). E – Positive Bcl-2 reaction in 
tumor tissue (LSAB x 200). F – High level of Ki-67 positivity in 
tumor tissue (LSAB x 400). LSAB – Labeled streptavidin biotin.
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the other three groups of patients according to the 
simultaneous examination of the p14/VEGF status 
(p=0.038). In addition, the tendency toward more fre-
quent local recurrences and metastasis was observed 
among patients with the simultaneous presence of ab-
errant methylation of p16 and high VEGF expression, 
and in the group of patients with a simultaneous pres-
ence of aberrant methylation of p14 and high VEGF 
expression (p=0.072 and p=0.075, respectively), rather 
than in the other patient groups. A better response to 
CRT was observed in the group of patients with si-
multaneous occurrence of p16 methylation, low VEGF 
and high EGFR expression (p=0.024). Furthermore, 
the absence of local recurrences and metastasis was 
significantly related to cases with the simultaneous 
occurrence of p16 methylation and high EGFR ex-
pression, as compared to the other three groups ac-
cording to the simultaneous examination of the p16/
Table 1. Correlation of p16 and p14 methylation status with clinicopathological parameters.
Variable p16 methylation status p p14 methylation status pM U M U
Age (yr. median) 63.846 ± 9.124 64.647 ± 8.082 0.720 66.7 ± 8.0 62.9 ± 8.7 0.095
Gender
Male
Female
18/38 (47.4%)
8/22 (36.4%)
20/38 (52.6%)
14/22 (63.6%) 0.797
14/37 (37.8%)
9/21(42.9%)
23/37 (62.2%)
12/21 (57.1%) 0.923
Tumor localizationa, b 
≤7 cmb
>7 cm
<7 cm>
6/13 (46.1%)
7/14 (50%)
13/32 (40.6%)
7/13 (53.8%)
7/14 (50%)
19/32 (59.4%)
0.828
6/13 (46.1%)
11/30 (33.7%)
6/14 (42.9%)
7/13 (53.8 %)
19/30 (63.3%)
8/14 (57.1%)
0.824
TNM stage before surgery
TNM II
TNM III
9/21 (42.7%)
17/39 (43.6%)
12/21 (57.1%)
22/39 (56.4%) 0.827
9/21 (42.9%)
14/37 (37.8%)
12/21 (57.1%)
23/37 (62.2%) 0.827
Response to neoadjuvant CRT
CR/PR
SD/PD
15/30 (50%)
11/30 (36.7%)
15/30 (50%)
19/30 (63.3%) 0.434
11/29 (37.9%)
12/29 (41.4%)
18/29 (62.1%)
17/29 (58.6%) 1.000
Local recurrence/metastasisa
Yes
No
8/24 (33.3%)
18/35 (51.4%)
16/24 (66.7%)
17/35 (48.6%) 0.286
13/24 (54.2%)
10/33 (30.3%)
11/24 (45.8%)
23/33 (69.7%) 0.124
M – methylated, U – unmethylated, CRT – chemoradiotherapy, CR – complete remission, PR – partial remission, SD – stable disease,  
PD – progressive disease. a Data are missing on one patient for given parameters. b The distance of the tumor from the anal verge. 
All p values were revealed by χ2-test or Fisher’s exact two-tailed test, when expected frequencies were lower than five
Table 2. Correlation of p16 and p14 methylation status with immunohistochemical parameters.
Protein expression
levels
p16 methylation status p p14 methylation status pM U M U
VEGF expressiona 
Low (< 10%)
High (≥ 10%)
16/30 (53.3%)
10/28 (35.7%)
14/30 (46.7%)
18/28 (64.3%) 0.278
11/29 (37.9%)
10/27 (37%)
18/29 (62.1%)
17/27 (63%) 0.836
EGFR expressiona
Low (< 25%)
High (≥ 25%)
16/41 (39%)
10/17 (58.8%)
25/41 (61%)
7/17 (41.2%) 0.276
14/40 (35%)
7/16 (43.7%)
26/40 (65%)
9/16 (56.3%) 0.760
Ki67 expressiona 
Low (< 10%)
High (≥ 10%)
4/15 (26.7%)
22/43 (51.2%)
11/15 (73.3%)
21/43 (48.8%) 0.180
5/15 (33.3%)
16/41 (39%)
10/15 (66.7%)
25/41 (61%) 0.938
Bcl-2 expressiona 
Low (< 10%)
High (≥ 10%)
20/40 (50%)
6/18 (33.3%)
20/40 (50%)
12/18 (66.7%) 0.371
15/39 (38.5%)
6/17 (35.3%)
24/39 (61.5%)
11/17 (64.7%) 0.940
M – methylated, U – unmethylated, VEGF – vascular endothelial growth factor, EGFR – epidermal growth factor receptor.
a Data are missing on two patients for given parameters. All p values were revealed by χ2-test or Fisher’s exact two-tailed test, when expected 
frequencies were lower than five.
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EGFR status (p=0.038). The power of the study for the 
observed statistically significant results was ≥0.80 at 
a significance level p<0.05.
Survival analysis 
Follow-up data was available for 53/60 patients from 
our study, and the median follow-up period was 23 
months (range 2-101 months). All death outcomes 
were cancer-related. Overall survival was significantly 
worse for patients who were in any of the following 
categories: higher VEGF expression (p=0.006), con-
current presence of high VEGF and low EGFR ex-
pression (p=0.007), no response to the neoadjuvant 
CRT (p=0.005), and occurrence of relapsed disease 
or distant metastasis (p<0.001). In all rectal cancer 
cases, we observed no significant difference in overall 
survival between patients with or without methylation 
of p16 (p=0.912, Fig. 3A) and p14 genes (p=0.911, 
Fig. 3B). Further, we examined the overall survival 
according to the simultaneous presence of aberrant 
methylation of either p16 or p14 genes and differ-
ent levels of expression of immunohistochemically 
determined parameters. The group of patients with 
a concurrent presence of p16 methylation and high 
VEGF expression showed significantly shorter overall 
survival when compared to the other three groups of 
patients (p=0.010, Fig. 3C). However, no such asso-
ciation was found in the case of patients with simul-
taneous p14 methylation and high VEGF expression 
(p=0.266, Fig. 3D). Concurrent occurrence of p16 or 
p14 methylation and different levels of Ki-67, Bcl-2 
and EGFR expression did not affect overall survival 
(results not shown).
DISCUSSION
Specific gene methylation patterns can alter responses 
to different therapeutic agents in solid tumors, includ-
ing colorectal cancer [21]. Methylation of p16 and p14 
genes is a relatively frequent molecular event in the 
pathogenesis of colorectal cancer but its clinical rel-
evance remains undetermined. Taking rectal cancer as 
a specific entity, only a few studies have investigated 
the role of p16 methylation status, while, as far as we 
know, our study is the first to investigate the potential 
predictive and prognostic value of aberrant p14 meth-
ylation status solely in this type of cancer.
The reported frequency of p16 and p14 gene pro-
moter hypermethylation in colorectal cancer ranges 
from 10% to 61% [15,22] and 28 to 50% [19,23-25], re-
spectively, and our results are in agreement with this. 
Thirty-eight out of 60 patients (60.3%) from our study 
had at least one methylated gene. Thus, our findings 
indicate that epigenetic alterations of these two genes 
are common events in rectal cancer and may be im-
portant to the pathogenesis of this tumor type.
We did not observe any association between the 
methylation statuses of p16 and p14 genes and the ex-
amined clinicopathological and immunohistochemical 
parameters. The association with the response to CRT 
or patient outcomes was not observed either. Existing 
literature data suggest that methylation of the p16 gene 
is associated with a more aggressive behavior of color-
ectal cancer [22,26]. Kim et al. [27] observed an asso-
ciation between p16 methylation and recurrence after 
curative operation in rectal cancer cases specifically, 
Fig. 3. Overall survival among rectal cancer patients according 
to the p16 or p14 methylation and VEGF expression status. A, 
B – No significant difference in overall survival between patients 
according to the methylation status of p16 and p14 gene, respec-
tively. C – The group of patients with concurrent occurrence of 
p16 methylation and high VEGF expression showed significantly 
shorter overall survival compared to the other three groups. D 
– No significant difference in overall survival between patients 
with simultaneous presence of p14 methylation and high VEGF 
expression and the other three groups.
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although preoperative CRT was not applied in these 
cases. According to the meta-analysis by Zhou et al. 
[28], no relationship was observed among aberrant p14 
gene methylation and pathological features in colorec-
tal cancer, except more prevalent p14 methylation in 
proximal colon cancers than in distal ones, while rec-
tum tumor location was not considered separately in 
the study. The situation regarding the role of p14 meth-
ylation status in colorectal disease outcome is less clear. 
While some studies reported p14 gene methylation 
alone [29] or in combination with p16 [23] as a marker 
of worse prognosis, other reports demonstrated that 
p14 gene methylation in combination with aberrant 
methylation of another panel of genes could be related 
to less aggressive colorectal pathogenesis [30]. These 
conflicting results reveal a need for further examina-
tion of the role of methylation of p16 and especially 
of p14 in rectal cancer. The fact that development of 
left- and right-sided colorectal cancers may involve dif-
ferent molecular mechanisms should be considered in 
future analyses, since research focusing on the mecha-
nisms behind different epigenetic profiles in colon vs 
rectum tumor location are rare [31].
A recent study of locally advanced rectal cancers 
by Kohonen-Corish et al. [32] indicated that p16 
methylation itself was not associated with poor sur-
vival, but the presence of both p16 methylation and 
Kirsten Rat Sarcoma virus (KRAS) mutation had an 
adverse effect on tumor recurrence and overall surviv-
al. Previously, we conducted KRAS mutation analyses 
on the same rectal cancer samples [20]; however, we 
found no association between p16 or p14 methyla-
tion and KRAS mutation status, or between the impact 
of these two events on therapy response and disease 
outcome.
In a more comprehensive analysis, we found that 
the simultaneous occurrence of either p16 or p14 
methylation and high VEGF expression was related 
to a more aggressive course of the disease, which was 
reflected in a significantly worse response to CRT and 
more frequent appearance of local recurrences and 
distant metastasis. In colorectal cancer, VEGF is as-
sociated with tumor aggressiveness and poor patient 
outcome [33,34], which is also demonstrated in our 
current study. The obtained result points to an impor-
tant role of VEGF in tumor development and p16 or 
p14 in tumor growth suppression. Products of p16 and 
p14 genes are now recognized as angiogenesis sup-
pressors that achieve antiangiogenic function via the 
modulation of VEGF expression [13,14]. Although we 
did not find an association between VEGF expression 
and p16 or p14 methylation status, our results suggest 
that simultaneous VEGF overexpression and p16 and/
or p14 gene methylation may distinguish the group 
of rectal cancers with a more aggressive biological 
behavior. We speculate that this could occur through 
induced tumor resistance to preoperative CRT. Nev-
ertheless, to clarify the direct biological relationship 
between p16, p14 and VEGF, additional studies of 
other regulatory genes included in the VEGF signal-
ing pathway are necessary. It is well known that genes 
such as KRAS and p53 also participate in the regu-
lation of VEGF expression [35,36]. However, in our 
recent report, a correlation between KRAS mutation 
status and VEGF expression was not found in locally 
advanced rectal cancer [20]. For future analyses, it 
would be useful to investigate the p53 gene status be-
cause the p53 pathway seems to have a more dominant 
role in rectal than in colon cancer [37].
In survival analysis, we observed that the group of 
patients with a concurrent presence of p16 methyla-
tion and high VEGF expression had a significantly 
shorter overall survival. Similar results were obtained 
in squamous cell carcinoma of the esophagus where 
the loss of p16 expression together with present ex-
pression of VEGF protein was associated with a higher 
cumulative postoperative survival rate [38]. The de-
termined association may be due to the more inva-
sive and progressive proliferation of cancer cells with 
p16 alterations due to disruption of cell cycle regu-
lation. Moreover, elevated VEGF expression, which 
was significantly related to shorter overall survival in 
our study, probably affects overall patient outcome 
indirectly through its proangiogenic effects. On the 
other hand, p14 methylation status in combination 
with VEGF expression did not influence the overall 
survival of patients included in our study, possibly due 
to the small number of preoperative biopsies analyzed 
and limited follow-up.
One interesting finding of our study is that in the 
group of patients with simultaneous p16 methylation 
and high EGFR expression, local recurrences and me-
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tastasis were significantly rare events. Moreover, in 
combined analysis including VEGF expression, we 
identified a subgroup of patients with concurrent p16 
methylation, low VEGF and high EGFR expression that 
displayed a better response to preoperative CRT. The 
underlying reasons for such a finding remain unclear 
and our results require further elucidation. Several au-
thors provided evidence that baseline EGFR expression 
was related to poor prognosis, poor tumor downstaging 
and local recurrence in rectal cancer [39-41], which 
was not the case in our study. Moreover, Zlobec et al. 
[42] found that the complete pathologic response was 
nearly six times more likely in EGFR-positive rectal 
tumors and they identified a group of VEGF-positive 
and EGFR-negative tumors that were highly resistant 
to treatment. In another study, Chakravarti et al. [43] 
showed that in patients with muscle-invasive bladder 
cancer, EGFR expression could also be a favorable prog-
nostic factor since EGFR positivity was significantly 
associated with improved overall survival and a ten-
dency toward reduced frequency of distant metasta-
sis. Considering this, we assumed that increased EGFR 
expression could provide better sensitivity to CRT and 
thus indirectly allow for a better response to therapy, 
although a high level of EGFR itself is not good in terms 
of rapid proliferation of tumor cells. Several previous 
reports have provided evidence that VEGF and EGFR 
signaling pathways are interrelated [43], while Ciardiel-
lo et al. [45] demonstrated that EGFR could upregulate 
VEGF expression. Although our results indicate that 
combined analysis of VEGF/EGFR expression and p16 
methylation status could define a subgroup of less ag-
gressive rectal cancers, further studies are needed to 
confirm our findings.
Our results, although limited by the small number 
of patients and short follow-up, suggest that methyla-
tion of p16 and p14 genes, which was found as a rela-
tively frequent epigenetic event among locally advanced 
rectal cancer patients studied, neither influences the 
response to CRT nor correlates with overall survival. 
However, after combined methylation analyses with 
different VEGF and EGFR expression levels in pretreat-
ment and preoperative specimens, the study revealed 
several subgroups of patients with a more or less ag-
gressive disease outcome, which could have potential 
predictive and/or prognostic relevance. Additional 
prospective studies of locally advanced rectal cancer 
are needed to clarify not only the clinical implications 
of p16 and p14 methylation, but also the relationships 
between aberrant methylation of these genes and VEGF 
mediated angiogenesis and EGFR signaling.
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